Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Persistent Genital Arousal Disorder (Men)

PGAD/GPD - Genito-Pelvic Dysesthesia, Unwanted Genital Arousal

Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
Not an FDA-regulated condition; no approved therapy

Reference only. Not medical advice.

What can go wrong

The core morbidity is psychological: high rates of depression, anxiety, catastrophization, and reported suicidality driven by relentless, unwanted sensation. There is no validated treatment algorithm and no controlled-trial evidence; patients are frequently misdiagnosed or dismissed. Any pharmacologic trial (e.g., discontinuing a suspected trigger such as trazodone) should be physician-supervised.

This is something to take to a clinician. The Atlas can tell you what is known about persistent genital arousal disorder (men) in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

PGAD/GPD is characterized by spontaneous, persistent, unwanted physical genital arousal (in men, sensations localized to the glans penis in over 80 percent of cases) occurring in the absence of sexual desire and not relieved by orgasm. Long considered a women's condition, isolated male cases are documented, most notably the first isolated male case report (Stevenson & Kohler, 2015, PMC4342067). The 2024 Fifth International Consultation on Sexual Medicine (ICSM) recommendations note similar prevalences across genders, but true male prevalence remains unknown due to stigma and underreporting.

Distressing, unwanted physical arousal without desire - and it does occur in men.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Recognition and workup of unwanted genital arousal
  • Differentiating from hypersexuality (it is not a desire disorder)

How it is supposed to work

The ICSM framework locates the driving lesion in one of five anatomical regions: region 1 the end organ (glans/dorsal nerve), region 2 the pelvis/perineum (pudendal), region 3 the cauda equina (Tarlov cysts, annular disc pathology), region 4 the spinal cord, and region 5 the brain. Sensory hyperactivity anywhere along this axis is perceived as genital arousal. Vascular, hormonal, pharmacologic (notably trazodone), and psychological contributors are also hypothesized.

What people get wrong

  • Often saidIt is just an extreme form of high libido

    ActuallyFalse. PGAD is arousal without desire - it is unwanted and distressing, categorically different from hypersexuality. Framing it as high libido is a common and harmful misdiagnosis.

Who profits, and who pushes back

  • Sexual Medicine Reviews (ICSM 2024 panel)

    Pushes backInternational expert consultation

    There is no standardized treatment algorithm; management is individualized to the presumed anatomical region of origin.

What we do not know

  • What is the true prevalence in men?
  • How often is a cauda-equina (region 3) lesion the actual driver?
  • Do any pharmacotherapies work better than symptom management?

At a glance

Symptom location (men)
Glans penis (>80%)
Character
Tingling, throbbing, near-constant
Relief with orgasm
No (or transient)

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Persistent Genital Arousal Disorder (Men). A short entry is not a safe entry.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.

Sources

The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.

The studies that matter

  • First isolated PGAD case in a male (Stevenson & Kohler)2015

    Documented isolated male PGAD, establishing it is not exclusively a female condition

  • ICSM 2024 recommendations (Sexual Medicine Reviews)2024

    Formalized PGAD/GPD across all genders and the 5-region anatomical framework

  • Treatment scoping review (PMC11492631)2024

    Confirmed absence of standardized, evidence-based treatment